跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

RAB0521

Sigma-Aldrich

牛IL2 / 白介素-2 ELISA试剂盒

for serum, plasma and cell culture supernatants

登录查看公司和协议定价


About This Item

UNSPSC代码:
41116158
NACRES:
NA.32

种属反应性

bovine

包装

kit of 96 wells (12 strips x 8 wells)

技术

ELISA: suitable

输入

sample type serum
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 0.2 ng/mL

检测方法

colorimetric

运输

wet ice

储存温度

−20°C

基因信息

bovine ... IL2(280822)

一般描述

This ELISA antibody pair detects bovine Interleukin-2.

应用

请参考Protocol了解详情。

其他说明

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

试剂盒组分也可单独购买

产品编号
说明
化学品安全说明书

  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)化学品安全说明书

  • RABSTOP3ELISA Stop Solution (Item I)化学品安全说明书

  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)化学品安全说明书

  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)化学品安全说明书

  • RABWASH420X Wash Buffer (Item B)化学品安全说明书

象形图

Corrosion

警示用语:

Warning

危险声明

预防措施声明

危险分类

Met. Corr. 1

储存分类代码

8A - Combustible corrosive hazardous materials

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Francesco Nannini et al.
Scientific reports, 10(1), 19168-19168 (2020-11-07)
Antibody phage display is a powerful platform for discovery of clinically applicable high affinity monoclonal antibodies against a broad range of targets. Libraries generated from immunized animals offer the advantage of in vivo affinity-maturation of V regions prior to library
Liping Qiu et al.
Small (Weinheim an der Bergstrasse, Germany), 14(15), e1703539-e1703539 (2018-03-02)
The activation of tumor-specific effector immune cells is key for successful immunotherapy and vaccination is a powerful strategy to induce such adaptive immune responses. However, the generation of effective anticancer vaccines is challenging. To overcome these challenges, a novel straight-forward
Tatsuo Matsuda et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(21), 5357-5367 (2018-05-04)
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells. Adoptive T-cell therapy with neoantigen-specific T-cell receptor (TCR)-engineered T cells would be an attractive therapeutic option for advanced
Pratiksha Gulati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(16), 3981-3993 (2018-05-12)
Purpose: Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM). Only most recently the issue of an optimally active chimeric antigen receptor
Sneha Ramakrishna et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(17), 5329-5341 (2019-05-22)
Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, the majority of post-CD22 CART remissions are short and associated with reduction in CD22 expression. We evaluate the implications

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门